Targeting cellular senescence with senotherapeutics: senolytics and senomorphics
The FEBS Journal · 2023-03 · 290 (5) · 1362-1383
DOI: 10.1111/febs.16350 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The FEBS Journal, 2022-02. Verfasst von Lei Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Molecular Biology and Biophysics, Institute on the Biology of Aging and Metabolism, University of Minnesota, Minneapolis,…. Hauptthemen laut MEDLINE: Senotherapeutics, Cellular Senescence. Die Arbeit wurde bisher 633-mal zitiert (Crossref) und nennt 183 Literaturangaben. Gefördert von: NIA NIH HHS, Michael J. Fox Foundation for Parkinson's Research, National Institute on Aging.
Abstract (Originalsprache)
The concept of geroscience is that since ageing is the greatest risk factor for many diseases and conditions, targeting the ageing process itself will have the greatest impact on human health. Of the hallmarks of ageing, cellular senescence has emerged as a druggable therapeutic target for extending healthspan in model organisms. Cellular senescence is a cell state of irreversible proliferative arrest driven by different types of stress, including oncogene‐induced stress. Many senescent cells (SnCs) develop a senescent‐associated secretory phenotype (SASP) comprising pro‐inflammatory cytokines, chemokines, proteases, bioactive lipids, inhibitory molecules, extracellular vesicles, metabolites, lipids and other factors, able to promote chronic inflammation and tissue dysfunction. SnCs up‐regulate senescent cell anti‐apoptotic pathways (SCAPs) that prevent them from dying despite the accumulation of damage to DNA and other organelles. These SCAPs and other pathways altered in SnCs represent therapeutic targets for the development of senotherapeutic drugs that induce selective cell death of SnCs, specifically termed senolytics or suppress markers of senescence, in particular the SASP, termed senomorphics. Here, we review the current state of the development of senolytics and senomorphics for the treatment of age‐related diseases and disorders and extension of healthy longevity. In addition, the challenges of documenting senolytic and senomorphic activity in pre‐clinical models and the current state of the clinical application of the different senotherapeutics will be discussed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, Molecular Biology and Biophysics, Institute on the Biology of Aging and Metabolism, University of Minnesota, Minneapolis, MN, USA.
ORCID-Profile: Lei Zhang, Paul D Robbins
Förderung
- NIA NIH HHS
- Michael J. Fox Foundation for Parkinson's Research
- National Institute on Aging
- Glenn Foundation for Medical Research
Zitieren
APA
Zhang, L., Pitcher, L. E., Prahalad, V., Niedernhofer, L. J., & Robbins, P. D. (2023). Targeting cellular senescence with senotherapeutics: senolytics and senomorphics. The FEBS Journal, 290(5), 1362-1383. https://doi.org/10.1111/febs.16350
Vancouver
Zhang L, Pitcher LE, Prahalad V, Niedernhofer LJ, Robbins PD. Targeting cellular senescence with senotherapeutics: senolytics and senomorphics. The FEBS Journal. 2023;290(5):1362-1383. doi:10.1111/febs.16350
BibTeX
@article{Zhang2023,
author = {Zhang, Lei and Pitcher, Louise E and Prahalad, Vaishali and Niedernhofer, Laura J and Robbins, Paul D},
title = {Targeting cellular senescence with senotherapeutics: senolytics and senomorphics},
journal = {The FEBS Journal},
year = {2023},
volume = {290},
number = {5},
pages = {1362--1383},
doi = {10.1111/febs.16350}
}
EUVIMED